Homo sapiens Protein: ADARB1 | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Summary | |||||||||||||||||||||||||||
InnateDB Protein | IDBP-583333.3 | ||||||||||||||||||||||||||
Last Modified | 2014-10-13 [Report errors or provide feedback] | ||||||||||||||||||||||||||
Gene Symbol | ADARB1 | ||||||||||||||||||||||||||
Protein Name | adenosine deaminase, RNA-specific, B1 | ||||||||||||||||||||||||||
Synonyms | ADAR2; DRABA2; DRADA2; RED1; | ||||||||||||||||||||||||||
Species | Homo sapiens | ||||||||||||||||||||||||||
Ensembl Protein | ENSP00000436367 | ||||||||||||||||||||||||||
InnateDB Gene | IDBG-5701 (ADARB1) | ||||||||||||||||||||||||||
Protein Structure |
![]() |
||||||||||||||||||||||||||
UniProt Annotation | |||||||||||||||||||||||||||
Function | Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer- associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site- specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis. {ECO:0000269PubMed:18178553, ECO:0000269PubMed:19908260, ECO:0000269PubMed:21289159}. | ||||||||||||||||||||||||||
Subcellular Localization | Nucleus. Nucleus, nucleolus. Note=Shuttles between nucleoli and the nucleoplasm. | ||||||||||||||||||||||||||
Disease Associations | |||||||||||||||||||||||||||
Tissue Specificity | Highly expressed in brain and heart and at lower levels in placenta. Fair expression in lung, liver and kidney. Detected in brain, heart, kidney, lung and liver (at protein level). Isoform 5 is high expressed in hippocampus and colon. Isoform 5 is expressed in pediatric astrocytomas and the protein has a decreased RNA-editing activity. The decrease in RNA editing correlates with the grade of malignancy of the tumors, with the high grade tumors showing lower editing is seen. {ECO:0000269PubMed:18178553, ECO:0000269PubMed:19156214, ECO:0000269PubMed:9149227}. | ||||||||||||||||||||||||||
Comments | |||||||||||||||||||||||||||
Interactions | |||||||||||||||||||||||||||
Number of Interactions |
This gene and/or its encoded proteins are associated with 22 experimentally validated interaction(s) in this database.
|
||||||||||||||||||||||||||
Gene Ontology | |||||||||||||||||||||||||||
Molecular Function |
|
||||||||||||||||||||||||||
Biological Process |
|
||||||||||||||||||||||||||
Cellular Component |
|
||||||||||||||||||||||||||
Protein Structure and Domains | |||||||||||||||||||||||||||
PDB ID | |||||||||||||||||||||||||||
InterPro |
IPR002466
Adenosine deaminase/editase IPR008996 Cytokine, IL-1-like IPR014720 Double-stranded RNA-binding domain |
||||||||||||||||||||||||||
PFAM |
PF02137
PF00035 |
||||||||||||||||||||||||||
PRINTS | |||||||||||||||||||||||||||
PIRSF | |||||||||||||||||||||||||||
SMART |
SM00552
SM00358 |
||||||||||||||||||||||||||
TIGRFAMs | |||||||||||||||||||||||||||
Post-translational Modifications | |||||||||||||||||||||||||||
Modification | |||||||||||||||||||||||||||
Cross-References | |||||||||||||||||||||||||||
SwissProt | P78563 | ||||||||||||||||||||||||||
PhosphoSite | PhosphoSite-P78563 | ||||||||||||||||||||||||||
TrEMBL | |||||||||||||||||||||||||||
UniProt Splice Variant | |||||||||||||||||||||||||||
Entrez Gene | 104 | ||||||||||||||||||||||||||
UniGene | Hs.674282 | ||||||||||||||||||||||||||
RefSeq | |||||||||||||||||||||||||||
HUGO | HGNC:226 | ||||||||||||||||||||||||||
OMIM | 601218 | ||||||||||||||||||||||||||
CCDS | CCDS33590 | ||||||||||||||||||||||||||
HPRD | 06777 | ||||||||||||||||||||||||||
IMGT | |||||||||||||||||||||||||||
EMBL | AB194370 AB194371 AB194372 AF001042 AF525422 AL133499 AL163301 AP001579 AY135659 BC065545 BX322560 CH471079 FJ169506 U76420 U76421 U76422 U82120 U82121 X99227 X99383 | ||||||||||||||||||||||||||
GenPept | AAB58300 AAB61686 AAB61687 AAC51240 AAC51241 AAC51242 AAH65545 AAM83100 AAN10291 ACN49027 BAE16326 BAE16327 BAE16328 CAA67611 CAA67762 CAB90493 EAX09357 EAX09359 EAX09360 | ||||||||||||||||||||||||||